<?xml version='1.0' encoding='utf-8'?>
<document id="23806476"><sentence text="Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions."><entity charOffset="76-89" id="DDI-PubMed.23806476.s1.e0" text="glibenclamide" /></sentence><sentence text="We studied if the clinical pharmacokinetics and drug-drug interactions (DDIs) of the sulfonylurea-derivative glibenclamide can be simulated via a physiologically-based pharmacokinetic modeling approach"><entity charOffset="85-97" id="DDI-PubMed.23806476.s2.e0" text="sulfonylurea" /><entity charOffset="109-122" id="DDI-PubMed.23806476.s2.e1" text="glibenclamide" /><pair ddi="false" e1="DDI-PubMed.23806476.s2.e0" e2="DDI-PubMed.23806476.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23806476.s2.e0" e2="DDI-PubMed.23806476.s2.e1" /></sentence><sentence text=" To this end, a glibenclamide PBPK-model was build in Simcyp using in vitro physicochemical and biotransformation data of the drug, and was subsequently optimized using plasma disappearance data observed after i"><entity charOffset="16-29" id="DDI-PubMed.23806476.s3.e0" text="glibenclamide" /></sentence><sentence text="v" /><sentence text=" administration" /><sentence text=" The model was validated against data observed after glibenclamide oral dosing, including DDIs"><entity charOffset="53-66" id="DDI-PubMed.23806476.s6.e0" text="glibenclamide" /></sentence><sentence text=" We found that glibenclamide pharmacokinetics could be adequately modeled if next to CYP metabolism an active hepatic uptake process was assumed"><entity charOffset="15-28" id="DDI-PubMed.23806476.s7.e0" text="glibenclamide" /></sentence><sentence text=" This hepatic uptake process was subsequently included in the model in a non-mechanistic manner" /><sentence text=" After an oral dose of 0" /><sentence text="875 mg predicted Cmax and AUC were 39" /><sentence text="7 (95% CI:37" /><sentence text="0-42" /><sentence text="7)ng/mL and 108 (95% CI: 96" /><sentence text="9-120)ng/mLh, respectively, which is in line with observed values of 43" /><sentence text="6 (95% CI: 37" /><sentence text="7-49" /><sentence text="5)ng/mL and 133 (95% CI: 107-159)ng/mLh" /><sentence text=" For a 1" /><sentence text="75 mg oral dose, the predicted and observed values were 82" /><sentence text="5 (95% CI:76" /><sentence text="6-88" /><sentence text="9)ng/mL vs 91" /><sentence text="1 (95% CI: 67" /><sentence text="9-115" /><sentence text="9) for Cmax and 224 (95% CI: 202-248) vs 324 (95% CI: 197-451)ng/mLh for AUC, respectively" /><sentence text=" The model correctly predicted a decrease in exposure after rifampicin pre-treatment"><entity charOffset="60-70" id="DDI-PubMed.23806476.s26.e0" text="rifampicin" /></sentence><sentence text=" An increase in glibenclamide exposure after clarithromycin co-treatment was predicted, but the magnitude of the effect was underestimated because part of this DDI is the result of an interaction at the transporter level"><entity charOffset="16-29" id="DDI-PubMed.23806476.s27.e0" text="glibenclamide" /><entity charOffset="45-59" id="DDI-PubMed.23806476.s27.e1" text="clarithromycin" /><pair ddi="false" e1="DDI-PubMed.23806476.s27.e0" e2="DDI-PubMed.23806476.s27.e0" /><pair ddi="false" e1="DDI-PubMed.23806476.s27.e0" e2="DDI-PubMed.23806476.s27.e1" /></sentence><sentence text=" Finally, the effects of glibenclamide and fluconazol co-administration were simulated"><entity charOffset="25-38" id="DDI-PubMed.23806476.s28.e0" text="glibenclamide" /><entity charOffset="43-53" id="DDI-PubMed.23806476.s28.e1" text="fluconazol" /><pair ddi="false" e1="DDI-PubMed.23806476.s28.e0" e2="DDI-PubMed.23806476.s28.e0" /><pair ddi="false" e1="DDI-PubMed.23806476.s28.e0" e2="DDI-PubMed.23806476.s28.e1" /></sentence><sentence text=" Our simulations indicated that co-administration of this potent CYP450 inhibitor will profoundly increase glibenclamide exposure, which is in line with clinical observations linking the glibenclamide-fluconazol combination to an increased risk of hypoglycemia"><entity charOffset="107-120" id="DDI-PubMed.23806476.s29.e0" text="glibenclamide" /><entity charOffset="187-200" id="DDI-PubMed.23806476.s29.e1" text="glibenclamide" /><entity charOffset="201-211" id="DDI-PubMed.23806476.s29.e2" text="fluconazol" /><pair ddi="false" e1="DDI-PubMed.23806476.s29.e0" e2="DDI-PubMed.23806476.s29.e0" /><pair ddi="false" e1="DDI-PubMed.23806476.s29.e0" e2="DDI-PubMed.23806476.s29.e1" /><pair ddi="false" e1="DDI-PubMed.23806476.s29.e0" e2="DDI-PubMed.23806476.s29.e2" /><pair ddi="false" e1="DDI-PubMed.23806476.s29.e1" e2="DDI-PubMed.23806476.s29.e1" /><pair ddi="false" e1="DDI-PubMed.23806476.s29.e1" e2="DDI-PubMed.23806476.s29.e2" /></sentence><sentence text=" In conclusion, glibenclamide pharmacokinetics and its CYP-mediated DDIs can be simulated via PBPK-modeling"><entity charOffset="16-29" id="DDI-PubMed.23806476.s30.e0" text="glibenclamide" /></sentence><sentence text=" In addition, our data underline the relevance of modeling transporters on a full mechanistic level to further improve pharmacokinetic and DDI predictions of this sulfonylurea-derivative"><entity charOffset="163-175" id="DDI-PubMed.23806476.s31.e0" text="sulfonylurea" /></sentence><sentence text="" /></document>